Zacks.com on MSN
Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know
Astrazeneca (AZN) closed at $164.52 in the latest trading session, marking a -2.59% move from the prior day. This change ...
In the latest trading session, Astrazeneca (AZN) closed at $201.21, marking a -1.55% move from the previous day. This move lagged the S&P 500's daily gain of 0.8%. Elsewhere, the Dow saw a downswing ...
AP surges on strong orders, AZN plunges after trial miss, LEVI slips on tariff outlook, MDA drops on dilution—read more.
AstraZeneca (LSE:AZN) has agreed a new five year national partnership with YMCA of the USA to expand community based cancer education, screening, and survivorship support. The company also received US ...
Zacks Investment Research on MSN
AZN inks deal with Dizal to in-license rights to lung cancer drug
AstraZeneca AZN announced that it has entered into an exclusive license agreement with China-based pharmaceutical company ...
On July 9, 2026, AstraZeneca (NYSE: AZN) stock fell more than 8% premarket after the Company announced that the Phase III CARDIO-TTransform trial of Wainua missed its primary endpoint in ATTR ...
AstraZeneca (LSE:AZN) shares have been in focus after fresh collaboration news, with investors weighing how new research ...
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
AstraZeneca pays $600M for global rights to Dizal’s lung cancer drug Zegfrovy, boosting its oncology pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results